Last updated: 6 October 2022 at 4:18pm EST

David Johnson Net Worth




The estimated Net Worth of David Lee Johnson is at least $7.19 Million dollars as of 1 September 2022. Mr. Johnson owns over 4,971 units of Global Blood Therapeutics stock worth over $4,005,775 and over the last 6 years he sold GBT stock worth over $0. In addition, he makes $3,186,910 as Chief Commercial Officer at Global Blood Therapeutics.

Mr. Johnson GBT stock SEC Form 4 insiders trading

David has made over 15 trades of the Global Blood Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 4,971 units of GBT stock worth $340,464 on 1 September 2022.

The largest trade he's ever made was exercising 6,770 units of Global Blood Therapeutics stock on 1 August 2022 worth over $463,677. On average, David trades about 3,511 units every 51 days since 2019. As of 1 September 2022 he still owns at least 58,487 units of Global Blood Therapeutics stock.

You can see the complete history of Mr. Johnson stock trades at the bottom of the page.





David Johnson biography

David Louis Johnson serves as Chief Commercial Officer of the Company. From October 2003 until February 2018, Mr. Johnson served in roles of increasing responsibility in the commercial organization at Gilead Sciences, Inc., a biopharmaceutical company, ultimately as vice president, sales and marketing, for Gilead’s Liver Disease Business Unit. At Gilead, Mr. Johnson was responsible for the commercial launch of Gilead’s hepatitis C treatments Sovaldi®, Harvoni®, Epclusa® and Vosevi®, hepatitis B treatment Vemlidy®, and HIV treatments Complera® and Stribild®. Prior to Gilead, from April 1992 to September 2003, Mr. Johnson served in various roles in sales, product marketing, business development, global commercial strategy and portfolio development at GlaxoSmithKline PLC, a British pharmaceutical company. Mr. Johnson holds a B.A. in business marketing from the University of Puget Sound and an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina.

What is the salary of David Johnson?

As the Chief Commercial Officer of Global Blood Therapeutics, the total compensation of David Johnson at Global Blood Therapeutics is $3,186,910. There are 4 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.



How old is David Johnson?

David Johnson is 51, he's been the Chief Commercial Officer of Global Blood Therapeutics since 2018. There are 17 older and 3 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.

What's David Johnson's mailing address?

David's mailing address filed with the SEC is C/O GLOBAL BLOOD THERAPEUTICS, INC., 181 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Global Blood Therapeutics

Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third..., and Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.



What does Global Blood Therapeutics do?

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.



What does Global Blood Therapeutics's logo look like?

Global Blood Therapeutics Inc. logo

Complete history of Mr. Johnson stock trades at Global Blood Therapeutics

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
1 Sep 2022 David Lee Johnson
Chief Commercial Officer
Option 4,971 $68.15 $338,774
1 Sep 2022
58,487
1 Aug 2022 David Lee Johnson
Chief Commercial Officer
Option 6,770 $32.40 $219,348
1 Aug 2022
55,493
1 Apr 2022 David Lee Johnson
Chief Commercial Officer
Option 4,375 $35.91 $157,106
1 Apr 2022
49,937
1 Mar 2022 David Lee Johnson
Chief Commercial Officer
Option 2,763 $29.87 $82,531
1 Mar 2022
46,518
1 Feb 2022 David Lee Johnson
Chief Commercial Officer
Option 6,770 $29.33 $198,564
1 Feb 2022
45,842
1 Oct 2021 David Lee Johnson
Chief Commercial Officer
Option 4,375 $26.25 $114,844
1 Oct 2021
41,242
1 Sep 2021 David Lee Johnson
Chief Commercial Officer
Option 2,762 $29.85 $82,446
1 Sep 2021
37,939
1 Aug 2021 David Lee Johnson
Chief Commercial Officer
Option 6,770 $27.33 $185,024
1 Aug 2021
37,039
1 Apr 2021 David Lee Johnson
Chief Commercial Officer
Option 4,375 $42.62 $186,463
1 Apr 2021
31,782
1 Feb 2021 David Lee Johnson
Chief Commercial Officer
Option 6,770 $49.49 $335,047
1 Feb 2021
29,490
1 Oct 2020 David Lee Johnson
Chief Commercial Officer
Option 4,375 $57.96 $253,575
1 Oct 2020
24,890
1 Aug 2020 David Lee Johnson
Chief Commercial Officer
Option 6,770 $67.48 $456,840
1 Aug 2020
23,133
1 Apr 2020 David Lee Johnson
Chief Commercial Officer
Option 4,375 $48.73 $213,194
1 Apr 2020
17,560
1 Feb 2020 David Lee Johnson
Chief Commercial Officer
Option 3,125 $65.26 $203,938
1 Feb 2020
14,352
1 Oct 2019 David Lee Johnson
Chief Commercial Officer
Option 4,375 $46.99 $205,581
1 Oct 2019
12,454


Global Blood Therapeutics executives and stock owners

Global Blood Therapeutics executives and other stock owners filed with the SEC include: